Dyslexia treatments sales will strengthen through 2036, anchored by cyclizine based drugs at a 36.0% share in 2026 as the leading drug type segment. Hospital pharmacies lead the distribution channel segment with a 45.0% share. The market is expected to reach USD 5.23 billion in 2026 and USD 9.63 billion by 2036.